TCF.L Stock - Theracryf Plc
Unlock GoAI Insights for TCF.L
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $396,000 | $442,000 | N/A | $194,000 |
| Gross Profit | $-2,112,000 | $385,000 | $429,000 | $-16,000 | $-3,195,000 |
| Gross Margin | N/A | 97.2% | 97.1% | N/A | -1646.9% |
| Operating Income | $-2,124,000 | $-3,560,000 | $-5,070,000 | $-3,191,000 | $-3,204,000 |
| Net Income | $-1,941,000 | $-3,137,000 | $-4,043,000 | $-2,730,000 | $-2,674,000 |
| Net Margin | N/A | -792.2% | -914.7% | N/A | -1378.4% |
| EPS | $-0.00 | $-0.01 | $-0.01 | $-0.01 | $-0.02 |
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company's lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase I clinical trials for the treatment of neurodevelopmental disorders and glioblastoma, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addiction and anxiety; and atypical dopamine transporter inhibitor (DAT), which is in late preclinical stage targeting fatigue and narcolepsy. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
Visit WebsiteEarnings History & Surprises
TCF.LEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q4 2025 | Dec 3, 2025 | — | $-0.00 | — | — |
Q2 2025 | Jun 3, 2025 | — | — | — | — |
Q4 2024 | Nov 28, 2024 | — | $-0.00 | — | — |
Q2 2024 | May 28, 2024 | — | $-0.01 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.01 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.01 | — | — |
Q3 2022 | Sep 29, 2022 | — | $-0.01 | — | — |
Q1 2022 | Mar 30, 2022 | — | $-0.00 | — | — |
Q3 2021 | Sep 29, 2021 | — | $-0.01 | — | — |
Q1 2021 | Mar 30, 2021 | — | $-0.00 | — | — |
Q3 2020 | Sep 29, 2020 | — | $-0.01 | — | — |
Q1 2020 | Mar 30, 2020 | — | $-0.01 | — | — |
Q4 2019 | Dec 17, 2019 | — | $-0.01 | — | — |
Latest News
Frequently Asked Questions about TCF.L
What is TCF.L's current stock price?
What is the analyst price target for TCF.L?
What sector is Theracryf Plc in?
What is TCF.L's market cap?
Does TCF.L pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to TCF.L for comparison